Molnar Miklos Z, Joglekar Kiran, Jiang Yu, Cholankeril George, Abdul Mubeen Khan Mohammed, Kedia Satish, Gonzalez Humberto C, Ahmed Aijaz, Singal Ashwani, Bhamidimarri Kalyan Ram, Aithal Guruprasad Padur, Duseja Ajay, Wong Vincent Wai-Sun, Gulnare Agayeva, Puri Puneet, Nair Satheesh, Eason James D, Satapathy Sanjaya K
Division of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN.
Department of Surgery, University of Tennessee Health Science Center, Memphis, TN.
Liver Transpl. 2019 Mar;25(3):399-410. doi: 10.1002/lt.25367.
Nonalcoholic steatohepatitis (NASH) is one of the top 3 indications for liver transplantation (LT) in Western countries. It is unknown whether renal dysfunction at the time of LT has any effect on post-LT outcomes in recipients with NASH. From the United Network for Organ Sharing-Standard Transplant Analysis and Research data set, we identified 4088 NASH recipients who received deceased donor LT. We divided our recipients a priori into 3 categories: group 1 with estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m at the time of LT and/or received dialysis within 2 weeks preceding LT (n = 937); group 2 with recipients who had eGFR ≥30 mL/minute/1.73 m and who did not receive renal replacement therapy prior to LT (n = 2812); and group 3 with recipients who underwent simultaneous liver-kidney transplantation (n = 339). We examined the association of pretransplant renal dysfunction with death with a functioning graft, all-cause mortality, and graft loss using competing risk regression and Cox proportional hazards models. The mean ± standard deviation age of the cohort at baseline was 58 ± 8 years, 55% were male, 80% were Caucasian, and average exception Model for End-Stage Liver Disease score was 24 ± 9. The median follow-up period was 5 years (median, 1816 days; interquartile range, 1090-2723 days). Compared with group 1 recipients, group 2 recipients had 19% reduced trend for risk for death with a functioning graft (subhazard ratio [SHR], 0.81; 95% confidence interval [CI], 0.64-1.02) and similar risk for graft loss (SHR, 1.25; 95% CI, 0.59-2.62), whereas group 3 recipients had similar risk for death with a functioning graft (SHR, 1.23; 95% CI, 0.96-1.57) and graft loss (SHR, 0.18; 95% CI, 0.02-1.37) using an adjusted competing risk regression model. In conclusion, recipients with preserved renal function before LT showed a trend toward lower risk of death with a functioning graft compared with SLKT recipients and those with pretransplant severe renal dysfunction in patients with NASH.
非酒精性脂肪性肝炎(NASH)是西方国家肝移植(LT)的三大适应证之一。LT时的肾功能不全是否会对NASH受者的LT术后结局产生影响尚不清楚。我们从器官共享联合网络标准移植分析与研究数据集里,识别出4088例接受已故供体LT的NASH受者。我们将受者预先分为3组:第1组为LT时估计肾小球滤过率(eGFR)<30 mL/分钟/1.73 m²且/或在LT前2周内接受透析的受者(n = 937);第2组为eGFR≥30 mL/分钟/1.73 m²且在LT前未接受肾脏替代治疗的受者(n = 2812);第3组为接受同期肝肾联合移植的受者(n = 339)。我们使用竞争风险回归和Cox比例风险模型,研究了移植前肾功能不全与有功能移植物死亡、全因死亡率和移植物丢失之间的关联。队列在基线时的平均±标准差年龄为58±8岁,55%为男性,80%为白种人,终末期肝病模型平均评分异常为24±9分。中位随访期为5年(中位数为1816天;四分位间距为1090 - 2723天)。与第1组受者相比,第2组受者有功能移植物死亡风险降低19%(亚风险比[SHR],0.81;95%置信区间[CI],0.64 - 1.02),移植物丢失风险相似(SHR,1.25;95% CI,0.59 - 2.62),而使用校正竞争风险回归模型时第3组受者有功能移植物死亡风险相似(SHR,1.23;95% CI,0.96 - 1.57),移植物丢失风险(SHR, 0.18;95% CI, 0.02 - 1.37)相似。总之,与NASH患者中接受同期肝肾联合移植的受者以及移植前有严重肾功能不全的受者相比,LT前肾功能保留的受者有功能移植物死亡风险呈降低趋势。